After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...
Hosts David and Gina explore how scientists over the centuries unlocked the ability to edit our genes ...
Global Dental Equipment Market OverviewThe global dental equipment market is projected to grow at a rate of 5–6% over the next five years. Factors such as an aging population, particularly in ...
Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...
Cathie Wood lunged back into Roblox, with ARK buying up 78,096 shares spread across ARKK and ARKF, a whopping $7.9 million swing that quickly turned into her largest trade of the day. For perspective, ...
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, ...
A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in a phase III trial died, Intellia Therapeutics said. The news came days ...
Why is the Supreme Court’s suggestion for an autonomous online regulator important for your UPSC exam? What significance do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback